Diagnostics

Connor Campbell is the Co-Founder and CEO of Osler.

Prior to Osler, Connor was a Principal at Oxford Science Enterprises (a science business builder, and the preferred investment partner of the University of Oxford) and a Consultant for McKinsey & Company, where his work included supporting the Government of Sierra Leone in the wake of the Ebola health crisis.

Connor received a degree in Medical Sciences from the University of Oxford.

Tom Parenteau is the Chief Commercial Officer of Osler, where he is responsible for commercial strategy development and implementation, and overseeing product, marketing, business development, and sales, amongst other areas.

Previous roles, in his 25+ year career, include:

• Global Commercial Director, Point of Care at ThermoFisher – where he established and led the distribution and sales of point of care platforms to over 70 countries worldwide
• Senior Director of Global Product Marketing and Scientific Affairs at Alere, where he oversaw the Biosite Triage, Cholestech LDX and HemoSense INRatio portfolios
• Director of Global Marketing for Diagnostics at Novartis, where he focused on molecular infectious disease screening of the world’s blood supply
• Global Director of OEM & Diagnostics at ThermoFisher (Invitrogen), where he oversaw the selling and licensing of a wide product portfolio, to all major global diagnostic companies
• Several leadership roles at Bio-Rad Laboratories involving sales, marketing and business development

Tom received a degree in Biology and Chemistry from the University of Kentucky, and an MBA from Loyola University Chicago.

David Edington is the founding Chief Technology Officer of Osler, and has overall responsibility for research & development and technology strategy.

Previous roles include VP, R&D at DNA Electronics (the inventors of semiconductor-based DNA sequencing) and technical leadership of a range of diagnostic and drug delivery device development programmes at PA Consulting Group, including spin-outs of venture companies in the point of care diagnostics field.

David holds a PhD in Physics from the University of Edinburgh, UK which involved the development of optical instruments and spectroscopic techniques for the analysis of molecular liquids.

Paul Dixon is the Chief Financial Officer of Osler, where he is responsible for all of Osler’s finance, operations, and business support functions, as well as assisting with investor relations. 

Prior to Osler, Paul held Finance Director positions in M&A, Financial Services, and Sales and Lettings at Countrywide plc (a former FTSE 250 real estate group). Prior to Countrywide, Paul was a Senior Manager at KPMG, where he worked internationally in the fields of audit, financial reporting, and governance.

Paul is a Fellow Chartered Accountant of the ICAEW and received a Degree in Chemistry from the University of Oxford.

David Berry became non-executive Chairman of Osler's Board of Directors in 2023, and has been a non-executive member of the Board since 2022.

David is Founder and CEO of Valo Health, and since 2005 has worked at Flagship Pioneering, where he is a General Partner, focused on conceiving, creating, resourcing, and launching groundbreaking companies. David has co-founded more than 20 companies across life sciences and sustainability.

David has been broadly recognized as a world-leading innovator: elected as a Young Global Leader by the World Economic Forum, named as Innovator of the Year by MIT Technology Review from amongst its annual TR35 list, and selected as one of 12 Innovators Reshaping Reality by the U.S. State Department, alongside pioneers such as Tim Berners-Lee. He holds over 200 patents and patent applications, and he and his companies have been awarded with more than 150 additional awards and honours. David also serves on the United Nations Sustainable Development Solutions Network (UN SDSN), where he was a Founding Leadership Council Member.

David received his M.D. from Harvard Medical School and his Ph.D. from MIT in biological engineering, through the Health Sciences and Technology program, completing the fastest dual degree in the modern history of the program.

Amber Salzman has been a non-executive member of Osler's Board of Directors since 2020.

Amber is the CEO of Epic Bio, a gene regulation company, and sits on the Board of Aviado Bio, a gene therapy company, and Biotechnology Innovation Organization, an association that represents the biotechnology industry.

Amber began her career at GlaxoSmithKline, where she served as a member of the R&D Executive team, and was responsible for clinical trials globally, with 30,000+ active patients, a budget of $1.25B, and 1,600 employees worldwide. She then served as CEO of Cardiokine, where she successfully negotiated the sale of the company to Cornerstone Therapeutics (NASDAQ:CRTX). After Cardiokine, Amber launched Annapurna, a gene therapy company with rare disease assets that merged with Avalanche (NASDAQ:AAVL) to create Adverum Biotechnologies (NASDAQ:ADVM). Most recently, Amber took on leadership of Epic Bio. Concurrent with industry positions, Amber leads a non-profit medical research foundation focused on accelerating the development of therapies for adrenoleukodystrophy (ALD).

Amber received a PhD in Mathematics from Bryn Mawr College in Pennsylvania, and a degree in Computer Science from Temple University in Philadelphia.

Jim Wilkinson has been a non-executive member of Osler's Board of Directors since 2022.

Jim is the Chief Financial Officer of Oxford Science Enterprises, a science business builder, and the preferred investment partner of the University of Oxford. Jim joined Oxford Science Enterprises as CFO and Director at the time of founding in 2015 and was interim CEO from November 2019 to December 2020. Jim works closely with the investment team on all transactions (fundraises and exits) and oversees all central operations.

Jim has over 30 years of experience in the commercial sector. Prior to his role at Oxford Science Enterprises, he was the CFO of several listed companies, including Informa Group (where he was a founder director), Sportingbet, Johnson Service Group, and IBC Group. He was also CFO at Lonrho after it was taken private in 2013.

Jim trained as an accountant with Deloitte, where he worked for 8 years.

Andre Crawford-Brunt has been a non-executive member of Osler's Board of Directors since 2017.

Andre is the Founder and General Partner of Braavos Investment Advisors and a Director of Oxford Science Enterprises, a science business builder, and the preferred investment partner of the University of Oxford. Andre is an active individual investor, backing the likes of Jet.com and Kensho Technologies, and more recently top life-science start-ups.

Previously, Andre was the Global Head of Equity Trading at Deutsche Bank and a Director at Sygnia Asset Management.

Andre received a degree in Business Administration and Management from Rhodes University in South Africa.

Connor Campbell is the CEO and Co-Founder of Osler.

Prior to Osler, Connor was a Principal at Oxford Science Enterprises (a science business builder, and the preferred investment partner of the University of Oxford) and a Consultant for McKinsey & Company, where his work included supporting the Government of Sierra Leone in the wake of the Ebola health crisis.

Connor received a degree in Medical Sciences from the University of Oxford.

Paul Dixon is the Chief Financial Officer of Osler, where he is responsible for all of Osler’s finance, operations, and business support functions, as well as assisting with investor relations. 

Prior to Osler, Paul held Finance Director positions in M&A, Financial Services, and Sales and Lettings at Countrywide plc (a former FTSE 250 real estate group). Prior to Countrywide, Paul was a Senior Manager at KPMG, where he worked internationally in the fields of audit, financial reporting, and governance.

Paul is a Fellow Chartered Accountant of the ICAEW and received a Degree in Chemistry from the University of Oxford.